Clinical Pharmacy Specialist, Gastrointestinal Medical Oncology, Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX. Email:
Am J Manag Care. 2018 Apr;24(7 Suppl):S118-S124.
Cancer of the colon and rectum is now the third most common form of cancer in the United States in both women and men. Approximately 21% of patients with colorectal cancer (CRC) are diagnosed with metastatic spread upon initial presentation, and 50% to 60% of all patients with earlier stage CRC will eventually develop metastases. Advances in systemic therapies have improved overall survival for patients with metastatic CRC (mCRC), but with an increasing cost burden on the healthcare system. Patterns of treatment choice and resulting medical care usage and costs can differ depending on patient-specific characteristics, impacting overall patient care and healthcare usage. The economic burden associated with CRC and its management is affected by several factors, including stage of disease at diagnosis, patient age, time period studied, oncologic therapy choice, and point of view. Available data assessing cost impact have recently been emerging; however, they are complex to interpret given the substantial heterogeneity among study population and the types and duration of analyses.
在美国，结肠癌和直肠癌现在是男女中第三常见的癌症类型。大约 21%的结直肠癌（CRC）患者在初次就诊时被诊断为转移性扩散，所有早期 CRC 患者中有 50%至 60%最终会发展为转移。系统治疗的进步提高了转移性 CRC（mCRC）患者的总生存率，但也给医疗系统带来了越来越大的成本负担。治疗选择模式以及由此产生的医疗保健使用和成本可能因患者的具体特征而异，从而影响整体患者护理和医疗保健使用。与 CRC 及其管理相关的经济负担受到多种因素的影响，包括诊断时疾病的阶段、患者年龄、研究时间段、肿瘤治疗选择和观点。最近出现了评估成本影响的可用数据；然而，鉴于研究人群以及分析的类型和持续时间存在很大的异质性，这些数据解释起来很复杂。
